Quotient Clinical Celebrates its 50th RapidFACT™ Program
News Feb 06, 2014
RapidFACT was first developed in 2008, with the goal of transforming the processes by which drug product formulations are optimized. This service has now been proven to accelerate program timelines by at least 50 percent, and deliver significant associated cost savings. This has been achieved by the co-location of real-time GMP manufacturing and clinical testing, under Quotient’s Translational Pharmaceutics™ platform, which enables formulation selection to be underpinned by emerging clinical data.
RapidFACT has been successfully deployed in early development and life cycle management programs to develop oral, inhaled, dermal and ocular drug products. These programs have principally focussed on optimizing drug products for once- or twice-daily dosing, or on addressing problems related to poor solubility. RapidFACT studies have been commissioned by customers ranging from large pharmaceutical organizations to small biotechs in the USA, Europe and Japan.
Mark Egerton, CEO of Quotient Clinical, commented: "RapidFACT was launched in response to the challenges our customers told us they were confronting in their development programs. We are pleased that the potential benefits we identified in 2008 have translated into real timeline reductions and cost savings in all of our RapidFACT programs. Ultimately, this approach is helping our customers to address many of the R&D productivity issues prevalent in the industry today."
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018